News / Clinical Trials

Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns

Intellia Therapeutics (NASDAQ:NTLA) has temporarily paused patient dosing and screening in its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and...